Floatz logo

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE

Opioid Dependence

Theresa Jacob, PhD, MPHSmall moleculePhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Opioid Dependence cohort.

Asset / SponsorPhaseRating
Buprenorphine
Erin Winstanley
Phase 4BBB
Buprenorphine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4BB
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
University of California, San Francisco
Phase 4BB
LIDOCAINE
University Medical Centre Ljubljana
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Denver Health and Hospital Authority
Phase 4BB

View all 39 →

Same molecule, other indications

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:

Low Back PainDormant
BBB
Indicative ·
74 / 100
View asset →
PainDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic OsteoarthritisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →